• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SIBN

    SI-BONE Inc.

    Subscribe to $SIBN
    $SIBN
    Medical/Dental Instruments
    Health Care

    SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: si-bone.com

    Recent Analyst Ratings for SI-BONE Inc.

    DatePrice TargetRatingAnalyst
    8/6/2024$27.00 → $19.00Buy
    Needham
    3/28/2024$25.00Overweight
    Piper Sandler
    10/12/2022$20.00Buy
    Jefferies
    4/7/2022$34.00Overweight
    Cantor Fitzgerald
    3/1/2022$30.00 → $28.00Overweight
    Morgan Stanley
    1/18/2022$43.00 → $36.00Buy
    B of A Securities
    12/21/2021$35.00 → $30.00Buy
    Truist Securities
    11/9/2021$42.00 → $36.00Market Outperform
    JMP Securities
    8/3/2021$41.00 → $40.00Overweight
    Morgan Stanley
    8/3/2021$42.00 → $37.00Buy
    Needham
    See more ratings

    SI-BONE Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025

      SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id92Nrrn.cfm. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast wil

      5/6/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

      First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing growth of 26.6%Gross margin of 79.7%, representing an improvement of 80 basis pointsNet loss of $6.5 million, representing an improvement of 40.0%Positive adjusted EBITDA of $0.5 million$144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million Recent Operational Highlights (any comparisons are to the prior year period) Over 1,400 active U.S. physicians with 300 physicians

      5/5/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

      SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/ueassh6s. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for a

      4/14/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

      SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26%  U.S. revenue of $46.9 million, representing growth of ~28%Gross margin of ~79%Net loss of $4.5 million, representing an improvement of ~59%Positive adjusted EBITDA of $1.9 million, representing an improvement of ~139%Ended the quarter with $150.0 million in cash and equivalents, representing $0

      2/24/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

      SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archi

      2/3/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

      Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024. Fourth Quarter 2024 Summary (any comparisons are to the prior year period) Worldwide revenue between $48.8 - $49.0 million, representing ~26% growthU.S. revenue between $46.7 - $46.9 million, representing ~28% growthEnded the quarter with ~1,390 active physicians in

      1/13/25 9:00:00 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

      SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.webcasts.com/starthere.jsp?ei=1696941&tp_key=589204a98b. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast

      11/20/24 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance

      SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (any comparisons are to the prior year period) Worldwide revenue of $40.3 million, representing growth of ~19%  U.S. revenue of $38.3 million, representing growth of ~18%Gross margin of ~79%Net loss of $6.6 million, representing an improvement of ~34%Adjusted EBITDA loss of $0.2 million, representing an improvement of ~94%Ended the quarter with $150.8 million in cash and equivalents, representing $0.7 million in net

      11/12/24 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™

      SANTA CLARA, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite™ (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment status, which will be effective up to three years beginning January 1, 2025, allows patient access to new and innovative technology l

      11/5/24 8:30:00 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    SI-BONE Inc. SEC Filings

    See more
    • SEC Form 144 filed by SI-BONE Inc.

      144 - SI-BONE, Inc. (0001459839) (Subject)

      5/7/25 4:21:02 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by SI-BONE Inc.

      10-Q - SI-BONE, Inc. (0001459839) (Filer)

      5/6/25 4:05:51 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SI-BONE, Inc. (0001459839) (Filer)

      5/5/25 4:12:45 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by SI-BONE Inc.

      DEFA14A - SI-BONE, Inc. (0001459839) (Filer)

      4/25/25 4:10:05 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by SI-BONE Inc.

      DEF 14A - SI-BONE, Inc. (0001459839) (Filer)

      4/25/25 4:08:51 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.

      SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      4/18/25 5:24:02 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.

      SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      4/17/25 9:35:38 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by SI-BONE Inc.

      S-8 - SI-BONE, Inc. (0001459839) (Filer)

      2/25/25 4:22:34 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by SI-BONE Inc.

      10-K - SI-BONE, Inc. (0001459839) (Filer)

      2/25/25 4:10:22 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SI-BONE, Inc. (0001459839) (Filer)

      2/24/25 4:27:11 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    SI-BONE Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

      Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help

      12/14/21 8:00:00 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors

      SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa

      4/19/21 7:00:49 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE Announces Senior Leadership Changes and Record Quarterly Revenue

      Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman; and Tony Recupero to Become President. SANTA CLARA, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE” or the “Company”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. As CEO, Laura Francis will succeed Jeff Dunn, who will remain with the Company as Execut

      1/7/21 7:00:00 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    SI-BONE Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on SI-BONE with a new price target

      Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously

      8/6/24 8:40:50 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on SI-BONE with a new price target

      Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00

      3/28/24 7:47:33 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on SI-BONE with a new price target

      Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00

      10/12/22 9:04:16 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald resumed coverage on SI-BONE with a new price target

      Cantor Fitzgerald resumed coverage of SI-BONE with a rating of Overweight and set a new price target of $34.00

      4/7/22 8:59:50 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley reiterated coverage on SI-BONE with a new price target

      Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $28.00 from $30.00 previously

      3/1/22 10:24:27 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • B of A Securities reiterated coverage on SI-BONE with a new price target

      B of A Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $36.00 from $43.00 previously

      1/18/22 9:56:39 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Truist Securities reiterated coverage on SI-BONE with a new price target

      Truist Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $30.00 from $35.00 previously

      12/21/21 7:31:11 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • JMP Securities reiterated coverage on SI-BONE with a new price target

      JMP Securities reiterated coverage of SI-BONE with a rating of Market Outperform and set a new price target of $36.00 from $42.00 previously

      11/9/21 8:22:45 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley reiterated coverage on SI-BONE with a new price target

      Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $40.00 from $41.00 previously

      8/3/21 9:03:48 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Needham reiterated coverage on SI-BONE with a new price target

      Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $37.00 from $42.00 previously

      8/3/21 5:56:13 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    SI-BONE Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Francis Laura sold $661,368 worth of shares (38,504 units at $17.18) (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      5/9/25 7:01:42 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Maheshwari Anshul sold $599,033 worth of shares (33,287 units at $18.00), decreasing direct ownership by 12% to 237,006 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      5/9/25 7:00:36 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Director Dunn Jeffrey W sold $4,628 worth of shares (336 units at $13.78), decreasing direct ownership by 3% to 12,536 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      5/2/25 5:08:52 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A exercised 21,367 shares at a strike of $4.68, increasing direct ownership by 9% to 266,245 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      5/2/25 5:07:56 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A sold $44,219 worth of shares (3,128 units at $14.14), decreasing direct ownership by 1% to 244,878 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      4/4/25 5:14:08 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • President, Commercial Ops Recupero Anthony J sold $46,853 worth of shares (3,311 units at $14.15), decreasing direct ownership by 1% to 284,555 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      4/4/25 5:13:36 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Maheshwari Anshul sold $46,723 worth of shares (3,311 units at $14.11), decreasing direct ownership by 1% to 270,293 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      4/4/25 5:12:42 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • New insider Pisetsky Michael A claimed ownership of 248,006 shares (SEC Form 3)

      3 - SI-BONE, Inc. (0001459839) (Issuer)

      3/24/25 7:40:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Francis Laura sold $795,915 worth of shares (46,233 units at $17.22), decreasing direct ownership by 8% to 506,761 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      2/21/25 4:19:27 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Maheshwari Anshul sold $188,518 worth of shares (11,180 units at $16.86), decreasing direct ownership by 4% to 273,604 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      2/21/25 4:18:48 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    SI-BONE Inc. Financials

    Live finance-specific insights

    See more
    • SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025

      SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id92Nrrn.cfm. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast wil

      5/6/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

      First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing growth of 26.6%Gross margin of 79.7%, representing an improvement of 80 basis pointsNet loss of $6.5 million, representing an improvement of 40.0%Positive adjusted EBITDA of $0.5 million$144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million Recent Operational Highlights (any comparisons are to the prior year period) Over 1,400 active U.S. physicians with 300 physicians

      5/5/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

      SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/ueassh6s. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for a

      4/14/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

      SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26%  U.S. revenue of $46.9 million, representing growth of ~28%Gross margin of ~79%Net loss of $4.5 million, representing an improvement of ~59%Positive adjusted EBITDA of $1.9 million, representing an improvement of ~139%Ended the quarter with $150.0 million in cash and equivalents, representing $0

      2/24/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

      SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archi

      2/3/25 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

      SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.webcasts.com/starthere.jsp?ei=1696941&tp_key=589204a98b. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast

      11/20/24 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance

      SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (any comparisons are to the prior year period) Worldwide revenue of $40.3 million, representing growth of ~19%  U.S. revenue of $38.3 million, representing growth of ~18%Gross margin of ~79%Net loss of $6.6 million, representing an improvement of ~34%Adjusted EBITDA loss of $0.2 million, representing an improvement of ~94%Ended the quarter with $150.8 million in cash and equivalents, representing $0.7 million in net

      11/12/24 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

      SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/b8oqnu9r. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and availa

      10/22/24 4:09:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024

      SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/r-x6CjRnDNsnPR3wF7sxumTszz?domain=cc.webcasts.com. Live audio of the webcast will be available on the "Investors" section of the company's w

      8/22/24 4:30:00 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024

      SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/1f7GCNk84yt0E1qNsm3zxj?domain=wsw.com. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The

      8/6/24 8:30:00 AM ET
      $SIBN
      Medical/Dental Instruments
      Health Care

    SI-BONE Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SI-BONE Inc.

      SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      11/14/24 6:27:27 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SI-BONE Inc.

      SC 13G - SI-BONE, Inc. (0001459839) (Subject)

      11/14/24 4:43:38 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SI-BONE Inc.

      SC 13G - SI-BONE, Inc. (0001459839) (Subject)

      11/8/24 12:14:44 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SI-BONE Inc. (Amendment)

      SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      2/14/24 7:28:40 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SI-BONE Inc.

      SC 13G - SI-BONE, Inc. (0001459839) (Subject)

      2/14/24 5:07:02 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SI-BONE Inc. (Amendment)

      SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      2/13/24 3:44:10 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SI-BONE Inc. (Amendment)

      SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      2/9/24 3:12:45 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SI-BONE Inc. (Amendment)

      SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      1/24/24 2:27:13 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SI-BONE Inc. (Amendment)

      SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

      1/22/24 4:10:32 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SI-BONE Inc.

      SC 13G - SI-BONE, Inc. (0001459839) (Subject)

      5/11/23 4:57:10 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care